ENResearchers at Universitätsmedizin Greifswald have demonstrated in animal models that Anakinra, an already approved drug for rheumatoid arthritis, can reduce inflammation-induced damage in acute pancreatitis and slow progressive scarring in chronic pancreatitis. The study, published in the international scientific journal Advanced Science, identifies a critical molecular pathway linking initial tissue damage to immune responses and organ scarring. By blocking this mechanism with an established drug, scientists hope to pave the way for a faster clinical translation into new therapeutic options for severe pancreatic diseases.
The Challenge of Acute and Chronic Pancreatic Inflammation
The pancreas is a vital digestive and endocrine organ responsible for producing essential digestive enzymes and regulating blood sugar levels through hormone secretion. When acute inflammation occurs, digestive enzymes become prematurely activated within the pancreatic tissue itself, causing autodigestion. This process destroys healthy cells and triggers a sterile inflammatory cascade that can quickly spread throughout the organ. In severe forms of acute pancreatitis, systemic inflammatory responses can develop, potentially leading to multi-organ failure and requiring intensive medical intervention.
Chronic pancreatitis represents a long-term progressive condition characterized by recurrent or persistent pancreatic tissue inflammation. Over time, repeated inflammatory episodes lead to irreversible structural changes, where healthy functional pancreatic tissue is progressively replaced by dense fibrous scar tissue. This process, known as pancreatic fibrosis, severely impairs both the exocrine function and endocrine function of the organ. Patients suffering from chronic pancreatitis often experience debilitating abdominal pain, severe malnutrition, persistent digestive disturbances, and secondary diabetes mellitus.
Pancreatic inflammatory disorders affect individuals across diverse age groups and populations worldwide, presenting complex clinical challenges for patients and healthcare specialists alike. Common causes of acute and chronic pancreatitis include gallstone disease, excessive alcohol consumption, genetic predispositions, hypertriglyceridemia, autoimmune factors, and certain medications. Regardless of the underlying trigger, managing the condition requires specialized medical care. Understanding the biological mechanisms driving tissue damage and fibrosis is essential for developing targeted therapeutic strategies aimed at preserving organ function and improving patient outcomes.
Modern Treatment Standards and the Discovery at Greifswald
In contemporary German university hospitals, the management of acute pancreatitis relies primarily on supportive medical measures, including intensive intravenous fluid resuscitation, pain control, nutritional support, and close monitoring for complications such as infection or organ failure. For chronic pancreatitis, current clinical practice focuses on symptom relief, enzyme replacement therapy, nutritional optimization, pain management, and endoscopic or surgical interventions when ductal obstructions arise. However, despite these sophisticated supportive approaches, medicine has lacked targeted pharmacological therapies capable of directly interrupting the disease mechanisms that cause tissue destruction and progressive scarring.
To address this therapeutic gap, a research team led by Dr. Matthias Sendler from the Klinik und Poliklinik für Innere Medizin A at Universitätsmedizin Greifswald investigated the molecular cascade connecting initial cellular injury with immune activation and subsequent fibrosis. In their study published in Advanced Science, the researchers focused on Interleukin-1 alpha, abbreviated as IL-1α, a messenger molecule released by dying pancreatic cells. The team discovered that IL-1α acts as an alarm signal that activates localized fibroblasts in the tissue. These activated fibroblasts attract additional immune cells to the site of injury while simultaneously increasing their responsiveness to signals that stimulate the formation of scar tissue.
Dr. Matthias Sendler explained that IL-1α alerts the immune system through fibroblasts and concurrently prepares the organ for future scarring. The pivotal finding of the Greifswald team is that this destructive pathway can be effectively blocked using Anakinra, a drug already approved for treating chronic inflammatory conditions such as rheumatoid arthritis. By blocking the IL-1 receptor, Anakinra neutralizes the signaling effect of IL-1α. In animal models, treatment with Anakinra significantly reduced the infiltration of immune cells into the pancreas, decreased acute tissue damage, and suppressed the development of fibrous scar tissue in chronic models, thereby preserving more functional organ tissue.
This research effort reflects the long-standing scientific expertise in pancreatic research at Universitätsmedizin Greifswald. According to Dr. Matthias Sendler, the successful execution of such complex experimental studies was made possible by a dedicated collaborative team. Under the leadership of department head Prof. Teufel, the research division aims to expand its analytical capabilities and scientific scope further. Professor Karlhans Endlich, Scientific Board Director of Universitätsmedizin Greifswald, emphasized that the study represents a significant step from decoding basic disease mechanisms to developing tangible treatment concepts using a drug already clinically proven.
Clinical Translation and Perspectives for International Patients
Although the laboratory findings from Universitätsmedizin Greifswald offer promising insights, Dr. Matthias Sendler and his research team emphasize that the results obtained from animal and cell models cannot yet be directly applied to human patients. Clinical trials are necessary to rigorously evaluate whether Anakinra can safely and effectively prevent severe disease courses or slow down tissue scarring in humans. Future clinical investigations must determine the optimal therapeutic window, appropriate dosage regimens, and specific patient subgroups that stand to benefit most from IL-1 receptor blockade.
The fact that Anakinra is already approved and widely used in clinical practice for other indications represents a major advantage. Developing an entirely new pharmaceutical compound requires extensive safety testing, phase I trials, and many years of preclinical development. In contrast, evaluating an established drug with known pharmacological and safety profiles can significantly accelerate the clinical testing phase. If future clinical trials validate these findings, repurposing Anakinra could offer patients facing acute or chronic pancreatitis a targeted treatment option aimed at preserving organ function and improving quality of life.
For international patients seeking treatment in Germany for complex pancreatic conditions, German university hospitals remain at the forefront of combining high-standard clinical care with innovative research. Patients currently diagnosed with acute or chronic pancreatitis receive comprehensive multidisciplinary care based on established international guidelines. During consultations with German specialists, patients and their families can discuss current standard treatment protocols, inquire about ongoing clinical trials in pancreatic disease management, and evaluate whether novel therapeutic concepts may become available in the near future as clinical research progresses.
Source: Greifswalder Publikation international veröffentlicht